Considering the role of four months of rifampin in the treatment of latent tuberculosis infection

American Journal of Respiratory and Critical Care Medicine

Volumn 170, Issue 8, 2004, Pages 832-835

  Reichman, Lee B ^a   Lardizabal, Alfred ^a   Hayden, Christopher H ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CONTRACEPTIVE AGENT; CYCLOSPORIN; DAPSONE; DIGITALIS; GLUCOCORTICOID; ISONIAZID; KETOCONAZOLE; METHADONE; ORAL ANTIDIABETIC AGENT; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; WARFARIN;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; HUMAN; LIVER TOXICITY; MAINTENANCE THERAPY; MEDICAL SOCIETY; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; SHORT COURSE THERAPY; TUBERCULOSIS;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; COSTS AND COST ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; EMIGRATION AND IMMIGRATION; HEPATITIS, TOXIC; HUMANS; ISONIAZID; MICE; MYCOBACTERIUM TUBERCULOSIS; PATIENT COMPLIANCE; RIFAMPIN; TIME FACTORS; TUBERCULOSIS; UNITED STATES;

EID: 5144220365     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200405-584PP     Document Type: Review

References (40)

1. Centers for Disease Control and Prevention. Tuberculosis elimination revisited: obstacles, opportunities, and a renewed commitment. Advisory Council for the Elimination of Tuberculosis (ACET). MMWR Morb Mortal Wkly Rep 1999;48(RR-9):1-13.
2. Institute of Medicine. Ending neglect: the elimination of tuberculosis in the United States. Washington, DC: National Academy Press; 2000.
3. American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221-S247.
4. Jordan TJ, Lewitt EM, Montgomery RL, Reichman LB. Isoniazid as preventive therapy in HIV infected intravenous drug abusers. JAMA 1991;265:2987-2991.
5. Bucher HC, Griffith LE, Guyatt GH, Sudre P, Naef P, Sendi P, Battegay M. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999;13:501-507.
6. Comstock GW. Prevention of tuberculosis among tuberculin reactors: maximizing benefits, minimizing risks. JAMA 1986;256:2729-2730.
7. Nolan CM, Godberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-1018.
8. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003;168:443-447.
9. Centers for Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:735-739.
10. Gordin F, Chaisson RE, Matts JP, Miller C, Garcia ML, Hafner R, Valdespino JL, Coberly J, Schechter M, Klukowicz AJ, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. JAMA 2000;283:1445-1450.
11. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;3:S231-S279.
12. Fox W. Wither short-course chemotherapy? Br J Dis Chest 1981;75:331-357.
13. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985;66:219-225.
14. Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989;140:1189-1193.
15. Hong Kong Chest Service, Tuberculosis Research Centre, Madras, and British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxix regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992;145:36-41.
16. International Union Against Tuberculosis Committee on Prophylaxis Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982;60:555-564.
17. Comstock GW. How much isoniazid is needed for the prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999;3:847-850.
18. Polesky A, Farber HW, Gottlieb DJ, Park H, Levinson S, O'Connell JJ, McInnis B, Nieves RL, Bernardo J. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med 1996;154:1473-1477.
19. Villarino M, Ridzon R, Weismuller P, Elcock M, Maxwell R, Meador J, Smith PJ, Carson ML, Geiter L. Rifampin preventive therapy for tuberculosis infection. Am J Respir Crit Care Med 1997;155:1735-1738.
20. Livengood JR, Sigler TG, Foster LR, Bobst JG, Snider DE. Isoniazid-resistant tuberculosis: a community outbreak and report of a rifampin prophylaxis failure. JAMA 1985;253:2847-2849.
21. Vernon A, Burman W, Senator D, Khan A, Bozman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999;353:1843-1847.
22. Geiter LJ. Results of a randomized, controlled trial to assess the toxicity and patient adherence with two short course regimens for the prevention of tuberculosis, a two-month regimen of rifampin and pyrazinamide or a four-month regimen of rifampin only, in comparison with a control regimen of six-months-isoniazid. Ph.D. (Epi) thesis. Baltimore: School of Hygiene and Public Health, Johns Hopkins University, 1997: 180.
23. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003;167:1472-1477.
24. Centers for Disease Control and Prevention. Trends in tuberculosis morbidity - United States, 1992-2002. MMWR Morb Mortal Wkly Rep 2003;52:217-222.
25. World Health Organization. International Union against Tuberculosis and Lung Disease. Anti-tuberculosis drug resistance in the world, report no. 3. Geneva: WHO Stop TB 2004.
26. Khan K, Muennig P, Behta M, Zivin J. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002;347:1850-1859.
27. Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, Contave M, Johnson M, Davis H, Genter L, et al. Randomized trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998;351:786-792.
28. Davidow AL, Mangura BT, Napolitano EC, Reichman LB. Rethinking the socioeconomics and geography of tuberculosis among foreign-born residents of New Jersey, 1994-1999. Am J Public Health 2003;93:1007-1012.
29. Bock N. Tuberculosis in correctional facilities. In: Reichman LB, Hershfield EH, editors. Tuberculosis: a comprehensive international approach. 2nd ed. New York: Marcel Dekker; 2000. p. 645-660.
30. Reichman LB. On target: a tuberculosis control strategy whose time has come. Ann Intern Med 1999;131:617-618.
31. Tulsky JP, White MC, Dawson D, Hoynes TM, Goldenson J, Schecter G. Screening for tuberculosis in jail and clinic follow-up after release. Am J Public Health 1998;88:223-226.
32. Centers for Disease Control and Prevention. Tuberculosis Prevention in Drug-Treatment Centers and Correctional Facilities - Selected US Sites, 1990-1991. MMWR Morb Mortal Wkly Rep 1993;42:210-213.
33. White MC, Tulsky JP, Goldenson J, Portillo CJ, Kawamura M, Mendendez E. Randomized controlled trial of interventions to improve follow-up for latent tuberculosis infection after release from jail. Arch Intern Med 2002;162:1044-1050.
34. Nolan CM, Roll L, Goldberg SV, Elarth AM. Directly observed isoniazid preventive therapy for released jail inmates. Am J Respir Crit Care Med 1997;155:583-586.
35. Bandyopadhyay T, Murray H, Metersky ML. Cost-effectiveness of tuberculosis prophylaxis after release from short-term correctional facilities. Chest 2002;121:1771-1775.
36. Centers for Disease Control and Prevention. Prevention and control of tuberculosis in correctional facilities: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1996;45(No. RR-8) [inclusive page numbers].
37. Hayden CH, Mangura BT, Channer I, Patterson GE, Passannante MR, Reichman LB. Tuberculin testing and treatment of latent TB infection (LTBI) among long-term jail inmates. Journal of Correctional Health Care (In press)
38. Bhavaraju R, Pirog L. Increasing the efficacy of school-based directly observed therapy: from needs assessment to program implementation. Health Promotion Practice. July 2002;3:387-396.
39. Mohle-Boetani JC, Miller B, Halpern M, Trivedi A, Lesser J, Solomon S, Fenstersheib M. School-based screening for tuberculosis infection: a cost-benefit analysis. JAMA 1995;274:613-619.
40. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Morb Mortal Wkly Rep 1998;47:1-58.